Literature DB >> 27731521

Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?

Mijin Kim1, Young Nam Kim2, Won Gu Kim1, Suyeon Park1, Hyemi Kwon1, Min Ji Jeon1, Hyeon Seon Ahn3, Sin-Ho Jung4, Sun Wook Kim2, Won Bae Kim1, Jae Hoon Chung2, Young Kee Shong1, Tae Hyuk Kim2, Tae Yong Kim1.   

Abstract

OBJECTIVE: Age >45 years is included as a variable in the tumor, node, metastases (TNM) staging of differentiated thyroid cancer (DTC), but a higher cut-off value has been suggested to be more clinically relevant and prevent over-staging. We evaluated the optimal age cut-off to predict disease-specific survival (DSS) in patients with DTC. DESIGN AND PATIENTS: This cohort study included 6333 patients with DTC who underwent thyroid surgery at two tertiary referral centres between 1996 and 2005. The optimal age cut-off value between 45 and 65 years for prediction of DSS was assessed. The proportion of variation explained (PVE) and Harrell's c-index was calculated to compare the predictability of each model.
RESULTS: The median age of patients was 46·0 years (IQR 37·8-54·6), and 5498 (87%) were female. Median follow-up period was 10·0 years, and 10-year DSS rate was 98%. Using TNM staging with 45 years as the cut-off (TNM45), 10-year DSS rates of stage I-IV were 99·4%, 96·1%, 97·7% and 85·9%, respectively (PVE = 3·0%, Harrell's c-index = 0·693); and using 55 years as the cut-off (TNM55), 99·4%, 92·2%, 95·3% and 79·7%, respectively (PVE = 4·3%, Harrell's c-index = 0·776). On receiver operating characteristic curve analysis, the optimal age cut-off for prediction of DSS was 55·4 years (area under the curve = 0·837, P < 0·001). About 20% of patients were down-staged to stage I using TNM55 compared to that using TNM45.
CONCLUSIONS: The cut-off age of 55 years was more appropriate for TNM staging to achieve better predictability for DSS in patients with DTC. This change would prevent over-staging in low-risk patients and prevent over-aggressive treatment.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27731521     DOI: 10.1111/cen.13254

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

Review 1.  Total thyroidectomy versus thyroid lobectomy in the treatment of papillary carcinoma.

Authors:  Marco Raffaelli; Serena Elisa Tempera; Luca Sessa; Celestino Pio Lombardi; Carmela De Crea; Rocco Bellantone
Journal:  Gland Surg       Date:  2020-01

2.  The combination of ATA classification and FNA results can improve the diagnostic efficiency of malignant thyroid nodules.

Authors:  Zhenzhen Wang; Xiangying Zhu; Xiaohui Yu; Haixia Guan; Lei Zhao; Yixia Zhang; Yuge Li; Liang Sang; Yuchen Han; Yushu Li; Zhongyan Shan; Weiping Teng
Journal:  Endocr Connect       Date:  2020-09       Impact factor: 3.335

3.  Is Gross Extrathyroidal Extension to Strap Muscles (T3b) Only a Risk Factor for Recurrence in Papillary Thyroid Carcinoma? A Propensity Score Matching Study.

Authors:  Yongseon Kim; Yong-Seok Kim; Ja Seong Bae; Jeong Soo Kim; Kwangsoon Kim
Journal:  Cancers (Basel)       Date:  2022-05-11       Impact factor: 6.575

4.  Comparison of the prognostic value of AJCC cancer staging system 7th and 8th editions for differentiated thyroid cancer.

Authors:  Y J Morosán Allo; L Bosio; A Morejón; C Parisi; M C Faingold; V Ilera; A Gauna; G Brenta
Journal:  BMC Endocr Disord       Date:  2022-06-01       Impact factor: 3.263

5.  Surgical Methods and Social Factors Are Associated With Long-Term Survival in Follicular Thyroid Carcinoma: Construction and Validation of a Prognostic Model Based on Machine Learning Algorithms.

Authors:  Yaqian Mao; Yanling Huang; Lizhen Xu; Jixing Liang; Wei Lin; Huibin Huang; Liantao Li; Junping Wen; Gang Chen
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

6.  Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma.

Authors:  Luis Rene Quiroa Barreno; Julia Bette Homem de Mello; Mateus Camargo Barros-Filho; Ana Lucia Francisco; Thiago Celestino Chulam; Clovis Antonio Lopes Pinto; Joao Gonçalves-Filho; Luiz Paulo Kowalski
Journal:  Braz J Otorhinolaryngol       Date:  2020-09-12

7.  Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study.

Authors:  Min Ji Jeon; Won Gu Kim; Tae Hyuk Kim; Hee Kyung Kim; Bo Hyun Kim; Hyon Seung Yi; Eun Sook Kim; Hosu Kim; Young Nam Kim; Eun Heui Kim; Tae Yong Kim; Sun Wook Kim; Ho Cheol Kang; Jae Hoon Chung; Young Kee Shong; Won Bae Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2017-11-22

8.  Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system.

Authors:  Kwangsoon Kim; Jin Kyong Kim; Cho Rok Lee; Sang-Wook Kang; Jandee Lee; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung
Journal:  Ther Adv Endocrinol Metab       Date:  2020-05-19       Impact factor: 3.565

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.